A citation-based method for searching scientific literature

Michael C Heinrich, Robert G Maki, Christopher L Corless, Cristina R Antonescu, Amy Harlow, Diana Griffith, Ajia Town, Arin McKinley, Wen-Bin Ou, Jonathan A Fletcher, Christopher D M Fletcher, Xin Huang, Darrel P Cohen, Charles M Baum, George D Demetri. J Clin Oncol 2008
Times Cited: 491







List of co-cited articles
605 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
57

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,[...]. Lancet 2013
748
54

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
S Hirota, K Isozaki, Y Moriyama, K Hashimoto, T Nishida, S Ishiguro, K Kawano, M Hanada, A Kurata, M Takeda,[...]. Science 1998
49

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
48

PDGFRA activating mutations in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana J Griffith, Andrea Haley, Ajia Town,[...]. Science 2003
40

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Heikki Joensuu, Laura S McGreevey, Chang-Jie Chen, Annick D Van den Abbeele, Brian J Druker,[...]. J Clin Oncol 2003
34

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
B Liegl, I Kepten, C Le, M Zhu, G D Demetri, M C Heinrich, C D M Fletcher, C L Corless, J A Fletcher. J Pathol 2008
283
32

Gastrointestinal stromal tumours: origin and molecular oncology.
Christopher L Corless, Christine M Barnett, Michael C Heinrich. Nat Rev Cancer 2011
479
26

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Charles D Blanke, George D Demetri, Heikki Joensuu, Peter J Roberts, Burton L Eisenberg, Margaret von Mehren, Christopher D M Fletcher, Katrin Sandau,[...]. J Clin Oncol 2006
556
26

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Christopher L Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, Michael C Heinrich. J Clin Oncol 2005
548
26

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras C W Hogendoorn, Martine Van Glabbeke,[...]. Lancet 2004
25

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C Heinrich, Kouros Owzar, Christopher L Corless, Donna Hollis, Ernest C Borden, Christopher D M Fletcher, Christopher W Ryan, Margaret von Mehren, Charles D Blanke, Cathryn Rankin,[...]. J Clin Oncol 2008
404
24

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer,[...]. Clin Cancer Res 2014
96
23

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Cristina R Antonescu, Peter Besmer, Tianhua Guo, Knarik Arkun, Glory Hom, Beata Koryotowski, Margaret A Leversha, Philip D Jeffrey, Diann Desantis, Samuel Singer,[...]. Clin Cancer Res 2005
568
21

A precision therapy against cancers driven by KIT/PDGFRA mutations.
Erica K Evans, Alexandra K Gardino, Joseph L Kim, Brian L Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson,[...]. Sci Transl Med 2017
75
26

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Eva Wardelmann, Sabine Merkelbach-Bruse, Katharina Pauls, Nadja Thomas, Hans-Ulrich Schildhaus, Thomas Heinicke, Nicola Speidel, Torsten Pietsch, Reinhard Buettner, Daniel Pink,[...]. Clin Cancer Res 2006
257
20

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Suzanne George, Qian Wang, Michael C Heinrich, Christopher L Corless, Meijun Zhu, James E Butrynski, Jeffrey A Morgan, Andrew J Wagner, Edwin Choy, William D Tap,[...]. J Clin Oncol 2012
169
20

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary, Scott C Wise, Thomas J Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L Bulfer,[...]. Cancer Cell 2019
64
31

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Cristina R Antonescu, Ronald P DeMatteo, Kristen N Ganjoo, Robert G Maki, Peter W T Pisters, Chandrajit P Raut, Richard F Riedel, Scott Schuetze,[...]. J Natl Compr Canc Netw 2010
704
19

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M Mannan, Brian P Rubin, George D Demetri,[...]. Br J Cancer 2019
47
40

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Jean-Yves Blay, César Serrano, Michael C Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L Jones, Steven Attia, Gina D'Amato,[...]. Lancet Oncol 2020
62
30

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali,[...]. Eur J Cancer 2006
608
18

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Charles D Blanke, Cathryn Rankin, George D Demetri, Christopher W Ryan, Margaret von Mehren, Robert S Benjamin, A Kevin Raymond, Vivien H C Bramwell, Laurence H Baker, Robert G Maki,[...]. J Clin Oncol 2008
693
18

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Ketan S Gajiwala, Joe C Wu, James Christensen, Gayatri D Deshmukh, Wade Diehl, Jonathan P DiNitto, Jessie M English, Michael J Greig, You-Ai He, Suzanne L Jacques,[...]. Proc Natl Acad Sci U S A 2009
250
18

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Charles D Blanke, George D Demetri, Margaret von Mehren, Michael C Heinrich, Burton Eisenberg, Jonathan A Fletcher, Christopher L Corless, Christopher D M Fletcher, Peter J Roberts, Daniela Heinz,[...]. J Clin Oncol 2008
672
17

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
59
28

Biology of gastrointestinal stromal tumors.
Christopher L Corless, Jonathan A Fletcher, Michael C Heinrich. J Clin Oncol 2004
820
16


A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, Ching-Yao Yang, Chueh-Chuan Yen, Chin-Yuan Tzen, Li-Tzong Chen, Jen-Shi Chen. Oncotarget 2017
27
55

Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Markku Miettinen, Jerzy Lasota. Semin Diagn Pathol 2006
15

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Sosipatros A Boikos, Alberto S Pappo, J Keith Killian, Michael P LaQuaglia, Chris B Weldon, Suzanne George, Jonathan C Trent, Margaret von Mehren, Jennifer A Wright, Josh D Schiffman,[...]. JAMA Oncol 2016
152
15

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Eileen Shi, Juliann Chmielecki, Chih-Min Tang, Kai Wang, Michael C Heinrich, Guhyun Kang, Christopher L Corless, David Hong, Katherine E Fero, James D Murphy,[...]. J Transl Med 2016
100
15

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Philippe A Cassier, Elena Fumagalli, Piotr Rutkowski, Patrick Schöffski, Martine Van Glabbeke, Maria Debiec-Rychter, Jean-François Emile, Florence Duffaud, Javier Martin-Broto, Bruno Landi,[...]. Clin Cancer Res 2012
101
15

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran,[...]. JAMA 2012
573
14

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi,[...]. Lancet Oncol 2012
494
14

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Heikki Joensuu, Eva Wardelmann, Harri Sihto, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T Hartmann, Daniel Pink, Silke Cameron, Peter Hohenberger,[...]. JAMA Oncol 2017
67
20

Gastrointestinal stromal tumour.
Heikki Joensuu, Peter Hohenberger, Christopher L Corless. Lancet 2013
300
13

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,[...]. Lancet 2009
865
13

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
S George, J Y Blay, P G Casali, A Le Cesne, P Stephenson, S E Deprimo, C S Harmon, C N J Law, J A Morgan, I Ray-Coquard,[...]. Eur J Cancer 2009
244
12


Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.
Kjetil Søreide, Oddvar M Sandvik, Jon Arne Søreide, Vanja Giljaca, Andrea Jureckova, V Ramesh Bulusu. Cancer Epidemiol 2016
197
12

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Narasimhan P Agaram, Grace C Wong, Tianhua Guo, Robert G Maki, Samuel Singer, Ronald P Dematteo, Peter Besmer, Cristina R Antonescu. Genes Chromosomes Cancer 2008
242
12

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Ping Chi, Yu Chen, Lei Zhang, Xingyi Guo, John Wongvipat, Tambudzai Shamu, Jonathan A Fletcher, Scott Dewell, Robert G Maki, Deyou Zheng,[...]. Nature 2010
205
12

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, Emmanuelle Bompas, Philippe Cassier, Isabelle Ray-Coquard, Maria Rios, Antoine Adenis,[...]. Lancet Oncol 2016
60
20

Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Christopher D M Fletcher, Jules J Berman, Christopher Corless, Fred Gorstein, Jerzy Lasota, B Jack Longley, Markku Miettinen, Timothy J O'Leary, Helen Remotti, Brian P Rubin,[...]. Hum Pathol 2002
11

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S Rosen, Beatrice Seddon, Suayib Yalcin, Hans Gelderblom, Charles C Williams, Elena Fumagalli,[...]. Cancer 2015
53
20

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Peter Reichardt, George D Demetri, Hans Gelderblom, Piotr Rutkowski, Seock-Ah Im, Sudeep Gupta, Yoon-Koo Kang, Patrick Schöffski, Jochen Schuette, Denis Soulières,[...]. BMC Cancer 2016
36
30

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
Katherine A Janeway, Su Young Kim, Maya Lodish, Vânia Nosé, Pierre Rustin, José Gaal, Patricia L M Dahia, Bernadette Liegl, Evan R Ball, Margarita Raygada,[...]. Proc Natl Acad Sci U S A 2011
388
11

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Sebastian Bauer, Lynn K Yu, George D Demetri, Jonathan A Fletcher. Cancer Res 2006
201
11

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
B P Rubin, S Singer, C Tsao, A Duensing, M L Lux, R Ruiz, M K Hibbard, C J Chen, S Xiao, D A Tuveson,[...]. Cancer Res 2001
751
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.